With the explosion in popularity of GLP-1 drugs like Ozempic, another industry has popped up, claiming to offer “natural” ...

Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi discovered cells that protect the body from autoimmune diseases.

GLP-1 receptor agonists are being studied as a treatment for a variety of substance use disorders (SUDs). This 3-part series looks at the current evidence for the treatment of SUD, alcohol use ...

GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

This 3-part series looks at the current evidence for the treatment of SUDs. Part 2 reviews the use of GLP-1 receptor agonists and alcohol use disorder.

GLP-1 receptor agonists lead a new wave of therapeutic options that may benefit patients with osteoarthritis, according to ...

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findingsOn track for full data read out in the first half of ...

An expert discusses how the phase 3 LUNA 3 trial demonstrated that rilzabrutinib achieved durable platelet responses in 23% of patients while also being the first prospective trial to show significant ...